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Abstract
Neonatal anemia and iron deficiency are frequent founds in neonatal intensive 
care units (NICUs). The three major causes of anemia in neonates are blood loss, 
reduced red blood cell production, and increased degradation of the erythrocytes. 
Premature infants in ICUs have high levels of iron deficiency, and ascertaining the 
cause of anemia in this group of patients can be a challenge in clinical practice. This 
chapter provides an updated review of neonatal anemia. It will concern the patho-
physiology of neonatal anemia in term and preterm infants and a detailed discus-
sion of the traditional and innovative laboratory tests for diagnosis and assessment 
of this condition in the ICUs
Keywords: anemia of prematurity, hemolysis, neonatal anemia, neonatal intensive 
care, physiologic anemia
1. Introduction
Neonatal anemia is a frequent found in neonatal intensive care units (NICUs). 
The diagnostic approach for neonatal anemia must establish its underlying cause 
for determining the proper treatment. However, due to the complexity of patients 
under NICUs (prematurity, infections, other diseases, ventilatory support) and the 
variety of laboratory tests available, determine the cause of neonatal anemia could 
be a challenge for clinicians.
After birth, all infants experience a gradual decrease in hemoglobin that results 
in varying degrees of anemia. During the first weeks of life, the hemoglobin 
concentration decreases significantly as a consequence of the reduced production 
of erythrocytes due to reduced production of erythropoietin (EPO) and also by the 
decreased erythrocyte lifespan during this period. Although all neonates develop 
the physiologic anemia, preterm infants experience a greater degree of anemia, 
the anemia of prematurity, which results from a combination of physiologic and 
pathological factors.
The iatrogenic blood loss due to phlebotomy for laboratory testing in NCIU is 
an important contributor for the anemia of prematurity. Because low birth-weight 
and premature infants usually need close monitoring, they suffer the loss of great 
amounts of blood.
The three major non-physiologic causes of anemia in neonates are blood loss, 
reduced red blood cell production, and increased degradation of the erythrocytes.
The diagnostic approach usually includes the patient history (familial, maternal, 
patient), physical examination and laboratory tests.
This chapter is an updated review of neonatal anemia. It concerns the patho-
physiology of neonatal anemia, anemia of prematurity and non-physiological 
causes of anemia in NICUs patients.
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We also provide a detailed discussion of the traditional and innovative labora-
tory tests for diagnosis and assessment of this condition in the ICUs.
2. Developmental erythropoiesis
To properly understand the pathophysiology aspects of neonatal anemia, is 
essential to comprehend how the erythroid blood cells are formed during pregnancy 
and the extrauterine life.
The erythropoiesis in the fetus starts in the liver, with progenitors that migrate 
from the yolk sac and infiltrate the liver circulation. Approximately at the sixth 
week of gestation, the liver becomes the main hematopoietic site, remaining its 
role during the second trimester of pregnancy. After the sixth month of gestation, 
the bone marrow is the major site of erythropoiesis, gradually replacing the liver in 
this function until birth. [1, 2] Fetal erythropoiesis is an extremely active process, 
mainly during the last 2 months of gestation, where the red blood cell (RBC) 
production is 3 to 5 times greater than the healthy adult ones. [3].
The erythropoiesis process is regulated by cytokines and growth factors, where the 
erythropoietin (EPO) exerts a major role, working synergically with the other factors. 
EPO acts as the main regulator of erythropoiesis, leading to the differentiation, prolif-
eration and survival of red blood cells. In the fetuses, the liver is a primary site of EPO 
production, which is replaced by the kidney in the extrauterine life. The synthesis of 
EPO and its receptor (EPO-R) is not directly regulated by hemoglobin levels, but by 
the systemic availability of oxygen, in a strictly regulated feedback loop. [4].
During the first week of life, the hemoglobin levels of the term newborn infants 
start to decrease progressively for the next 6 to 8 weeks. This process occurs in 
both term and preterm neonates. The postnatal plasma levels of EPO exhibit a 
predictable pattern of change, which is inversely associated with hemoglobin 
levels. Also, there is a directly proportional association between the EPO levels and 
the reticulocyte counts. [5].
3. Physiologic anemia of the newborn
After birth, newborn infants undergo dramatic changes in tissue oxygenation. 
When the lungs replace the placenta as the source of oxygen, the arterial oxygen 
saturation increases about two-fold, which is followed by a decrease in EPO levels, 
resulting in the characteristic transient decay in hemoglobin levels, referred to as 
the “physiologic anemia of the newborn”. Furthermore, the reduction in hemoglo-
bin levels is also accompanied by a gradual decrease in the RBC count and the mean 
corpuscular volume (MCV). In term neonates, the physiologic anemia occurs at 4 
to 6 weeks of life, persisting until the hemoglobin levels falls to approximately 10 
to 11 g/dL, thus stimulating the EPO production and release by the kidneys, as a 
compensatory process. [6].
Full-term neonates have from 50 to 80% of hemoglobin F and 15 to 50% of 
hemoglobin A, yet the new erythrocytes produced after birth will contain mostly 
hemoglobin A, allowing better tissue oxygenation, as the last has higher oxygen 
affinity the hemoglobin F. Another adaptative mechanism that improves oxygen-
ation at this phase is the increase of 2,3-diphosphoglycerate concentration inside the 
erythrocytes, thus improving the oxygen release from hemoglobin. [5, 7].
The gradual decrease in EPO production is not described as the unique cause of 
the physiologic anemia of the newborn. Reduced red cell lifespan and hemodilution 




The main causes of the physiologic anemia of the newborn are presented in 
Figure 1.
Differently from normal adult erythrocytes that have a life span of 120 days, the 
neonate erythrocytes life span is only 60 to 90 days. [8] This shortened survival is 
attributed to greater sensitivity and osmotic hemolysis and oxidative injury than 
the adult red blood cells. The neonatal erythrocyte has lower levels of antioxidant 
enzymes such as glutathione peroxidase, increasing thus their susceptibility to 
oxidative stress, and subsequential formation of Heinz bodies and methemoglobin, 
which contributes to reducing their lifespan. [3, 9] Additionally, a process named 
neocytolysis is also responsible for the reduced life span of the erythrocytes. It con-
sists of the active removal of young erythrocytes generated in a relatively hypoxic 
condition when the individual is exposed to normoxic or hyperoxic conditions, as 
occurs in the change from placental to lung respiration. Furthermore, the higher 
concentration of hemoglobin F in the neonates is also responsible for the decreased 
life span of the neonatal erythrocyte, as this type of hemoglobin tends to denature 
and promote damage to the erythrocyte membrane from the inside. [10].
The hemodilution due to the increased blood volume following the rapid weight 
gain in the first months of life may also contribute to the physiologic anemia, 
although it is not clearly understood the impact of this factor in the decreased 
hemoglobin levels and RBC counts. [6].
4. Anemia in preterm infants
Although all neonates develop the physiologic anemia of the newborn, the 
preterm infants experience a greater degree of anemia, the anemia of prematurity, 
which results from a combination of physiologic and pathological factors.
The postnatal drop in hemoglobin levels occurs more rapidly in preterm 
infants, reaching the nadir before the term ones at 4 to 6 weeks, with approxi-
mately 7 to 8 g/dL, in contrast with hemoglobin levels of 10 to 11 g/dL at the nadir 
of those born in term, which generally occurs at 10 to 12 weeks of life. The hemo-
globin levels are gestational age dependent, thus, the more premature neonates, 
and the low-birth-weight ones, usually present deeper degrees of anemia. [11].
The diminished production of EPO in response to anemia in premature infants 
is believed to exert a key role in the pathophysiology of anemia of prematurity. 
This is partly explained by the fact that the liver is responsible for EPO produc-
tion in intrauterine life. The switch to kidneys as the main source of EPO does not 
occur right after birth as in the term infants. Thus, because the development of the 
Figure 1. 
Causes of physiologic anemia of the newborn.
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Figure 2. 
Non-physiologic causes of neonatal anemia.
preterm infant is not properly completed, after birth the liver continues to be the 
principal site of EPO production, which is known to be less responsive to hypoxia 
than the kidneys. An accelerated metabolism by clearance of EPO, which is from 
two to fourfold in preterm infants in comparison to adults, is also responsible 
for the reduced levels observed in preterm infants. Therefore, the reduced EPO 
levels in preterm infants are a result of both diminished production and increased 
metabolism [12].
The iatrogenic blood loss due to phlebotomy for laboratory testing in the inten-
sive care units is described by many authors as the main responsible for anemia 
of prematurity. [13–15] The practice of intensive care neonatology requires serial 
laboratory testing such as blood gases, electrolytes, hemocultures, hemogram. 
Because small premature infants usually need close monitoring, they suffer the loss 
of great amounts of blood.
In neonates, the total blood volume varies from 80 to 115 mL/kg, thus, a 10 mL 
blood sample can correspond to more than 10% of the total blood volume of a 
premature infant. [2] The first weeks of intensive care usually are the period when 
the greater amounts of blood are withdrawn. [16] In the NICUs, approximately 15 
to 30% of the total blood volume per week are required for laboratory tests. For 
extremely preterm infants, the iatrogenic blood loss is even greater, representing 
up to one-third of the total blood volume in the first month of life. [13] Also, there 
is a so-called “hidden” blood loss due to the sampling for laboratory tests, pres-
ent in cotton pads, gauze and the dead space of syringes, or tubing of butterfly 
needles. [17].
There is a significant correlation between the amounts of blood collected for 
laboratory testing and the volume of blood transfused in NICU patients, where the 
amount of blood transfused can be equal to or greater than the blood drawn, rein-
forcing the evidence that the iatrogenic blood loss is a major contributor to anemia 
in premature infants. [15].
Besides the iatrogenic blood loss, other non-physiologic conditions can aggravate 
the development of anemia in the neonatal period, such as blood loss, hemolysis, 




In the neonatal period, the causes of anemia are classified into 3 groups: blood 
loss, decreased erythrocyte production and increased erythrocyte destruction. The 
causes of neonatal anemia are resumed in Figure 2.
5. Blood loss
Blood loss in the neonates can occur before, during or after the delivery, by 
several mechanisms, associated with 5–10% of the cases of severe neonatal  
anemia [18].
During pregnancy, the passage of fetal blood cells to maternal circulation, 
which is called fetomaternal hemorrhage, occurs in 50% of all pregnancies without 
promoting any harm to the mother or the fetus. However, in about 1 to 10% of preg-
nancies, fetomaternal hemorrhage can be substantial, when the blood loss reaches 
40 to 100 mL. The fragile separation between the maternal and fetal circulation is 
described as the main mechanism behind fetomaternal hemorrhage before delivery. 
Fetomaternal hemorrhage also occurs during delivery, as a consequence of trauma 
and erosion to placental villi during labour. Other causes of fetomaternal hemor-
rhage include diagnostic amniocentesis, percutaneous umbilical blood sampling, 
and traumatic injury to the mother during pregnancy [11, 19].
Another cause of fetal hemorrhage before delivery is the twin-twin transfusion, 
which occurs in approximately one-third of all monozygotic, monochorionic twin 
pregnancies, with a mortality rate of approximately 15%. Twin-twin transfusion is 
responsible for considerable discrepancies of hemoglobin levels between the twins, 
usually greater than 5 g/dL, leading to simultaneous anemia and polycythemia. 
The donor twin usually presents low birth weight and may manifest congestive 
heart failure and shock. The receptor twin is at risk of hyperviscosity syndrome, 
disseminated intravascular coagulation, hyperbilirubinemia and respiratory 
distress [11, 20, 21].
In the intrapartum period, fetoplacental hemorrhage can occur, commonly 
when the infant is held above the placenta, as in cesarean section, before the cord 
clamping [11].
Cord malformations, such as velamentous insertion are associated with an 
increased risk of rupture of the blood cord vessels during labour, leading to signifi-
cant intrapartum hemorrhage. Placental abnormalities such as placenta previa and 
abruptio placentae can also result in significant maternal and fetal blood loss during 
delivery [17, 18, 20].
Internal hemorrhage in the newborn can be caused by trauma during birth, 
bleeding disorders, vitamin K deficiency, and congenital vascular malforma-
tions. The most common sites of internal hemorrhage in the neonate are the 
head, brain, lungs, liver, and less frequently spleen, and adrenals. Traumatic 
deliveries are frequently associated with subdural/subarachnoid hemorrhage and 
cephalhematoma [11, 18, 22, 23].
6. Hemolysis
An important contributor to neonatal anemia is the increased erythrocyte 
destruction by hemolysis, which is associated with congenital and acquired condi-
tions. In the neonatal period, hemolytic disorders can be classified as immune-
mediated hemolysis, red cell membrane defects, red cell enzymatic deficiencies and 
hemoglobinopathies.
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6.1 Immune mediated-hemolysis
Immune-mediate hemolysis occurs when fetal erythrocytes enter the maternal 
circulation, physiologically, by fetomaternal hemorrhage or amniocentesis. Surface 
antigens present in fetal red blood cells stimulates the maternal immune system 
to produce antibodies against them. Those antibodies are usually IgG, which 
can cross the placental barrier and enter the fetal circulation, marking the fetal 
erythrocytes for removal by the reticuloendothelial system. [18] The majority of 
cases of immune-mediated hemolysis in the neonatal period are result of ABO and 
Rh incompatibilities, where the Rh system is associated with more severe anemia. 
Other blood group systems like Kell and Duffy can also result in clinically relevant 
hemolysis [24].
6.2 Red cell membrane defects
Quantitative or qualitative disorders in red blood cell membrane proteins can 
impair erythrocyte deformability and stability, therefore leading to hemolysis.
Hereditary spherocytosis (HS) is the most common hemolytic anemia due to red 
blood cell membrane defect, which is usually transmitted as an autosomal domi-
nant trait. The central event in HS is the loss of membrane surface area, leading to 
reduced deformability, due to defects of membrane proteins ankyrin and spectrin, 
band 3 or protein 4.2. Abnormal spherocytes with impaired deformability are 
frequently trapped and destroyed in the spleen leading to hemolysis and thus to 
anemia and hyperbilirubinemia. In the neonatal period, hemolysis can be enhanced 
because hemoglobin F poorly binds 2,3 diphosphoglycerate, which remains in the 
free form, contributing to the destabilization of protein interactions in the eryth-
rocyte membrane. Anemia is the most frequent complication of HS in the neonatal 
period. Other consequences include cholelithiasis, hemolytic episodes, and aplastic 
crises [10, 18, 25, 26].
Hereditary elliptocytosis (HE) is a group of diseases that are characterized by 
the presence of elliptical erythrocytes in the peripheral blood, the main defects 
in this disease concern the alpha and beta spectrin, protein 4.1, band 3 and rarely 
glycophorin A. Although is more frequent than HS in the general population, 
HE is less likely to cause significant hemolysis and anemia. HE is usually asymp-
tomatic until 4–6 months of life, although neonatal hemolytic anemia, jaundice 
and fetal hydrops are also described. [10, 27, 28] Hereditary pyropoikilocytosis 
is a subtype of HE, where the erythrocyte morphology resembles those seen in 
the blood smear of patients after severe burns. It is more frequent in individuals 
of African descendance and causes severe anemia and hemolysis in the neonatal 
period [9].
6.3 Red cell enzymatic deficiencies
Defects in red blood cells enzymes production can induce damage and decrease 
the lifespan of erythrocytes. The most common is Glucose-6-pyruvate-kinase 
(G6PD) deficiency, a hereditary X linked recessive disorder that affects over 400 
million people in the world. G6PD catalyze the first reaction in the pentose phos-
phate pathway, responsible for NADPH production, which is essential to maintain 
adequate levels of reduced glutathione for protecting the erythrocyte from oxida-
tive stress. G6PD deficient erythrocytes are vulnerable to oxidative damage and 
hemolysis In the neonatal period, G6pD deficiency can result in significant hemo-
lytic anemia and hyperbilirubinemia that may require phototherapy and exchange 




The second enzymatic deficiency associated with neonatal hemolytic anemia 
is for pyruvate kinase (PK), an enzyme from the glycolytic pathway of the eryth-
rocyte, which is responsible for the generation of adenosine triphosphate (ATP). 
Therefore, PK deficiency reduces the amount of energy available for the erythro-
cytes, which cannot maintain their content of potassium and water, resulting in 
subsequent premature cell death. Most newborns with PK deficiency develop severe 
jaundice, hemolytic anemia and less frequently, liver dysfunction [10, 18, 31].
6.4 Hemoglobinopathies
Erythrocyte hemoglobin defects are also responsible for clinically relevant cases 
of neonatal anemia. Thalassemia is a group of genetic disorders of globin-chain 
production, that results in an imbalance between the α-globin and β-globin chain 
production. The α-thalassemia syndromes result from the deletion of one or more 
genes of the four α-globin genes, and its clinical manifestation will depend on the 
number of genes deleted. A single α-globin gene deletion results in a carrier state 
which is asymptomatic. Deletion of two genes results in α-thalassemia trait, which 
usually presents as microcytosis and mild anemia. Hemoglobin H disease results 
from the deletion of 3 α-globin genes. This leads to a significant imbalance between 
α and β chain production and the formation of hemoglobin H (β4) and hemoglobin 
Barts (γ4). Patients with hemoglobin H disease are often born with hypochromic, 
hemolytic anemia, and are at risk for significant neonatal hyperbilirubinemia. The 
deletion of all 4 α-globin genes results in homozygous α-thalassemia, with a high 
risk of intrauterine death, severe hemolytic anemia and hydrops fetalis [9, 10, 32].
Hemoglobin H is unstable and has an extremely high oxygen affinity and is thus 
unable to effectively deliver oxygen. It is also relatively unstable and causes ineffec-
tive erythropoiesis and hemolytic anemia, due to membrane injury from oxidative 
damage resulting in shortened red cell survival [33].
The β-globin chain defects, including sickle cell disease and β-thalassemia, 
are not usually associated with anemia or hemolysis during the neonatal period, 
because the erythrocytes of newborn infants contain large amounts of fetal hemo-
globin (α2γ2) [9].
7. Decreased erythrocyte production
7.1 Infections
Congenital infections are an important cause of neonatal anemia by decreased 
erythrocyte production. Parvovirus B19, a DNA virus with an affinity for erythroid 
progenitor cells can be vertically transmitted to the fetus during pregnancy in 
susceptible women, who represent approximately 35% of all pregnancies, leading 
to severe anemia, miscarriage, non-immune hydrops and stillbirth, although the 
majority of the cases is asymptomatic [20, 22].
Other congenital infections associated with anemia in the neonatal period are 
cytomegalovirus, syphilis and toxoplasmosis [34–36].
7.2 Nutritional deficiencies
Although iron deficiency is not a common issue in the neonatal period for 
full-term infants, as the neonatal iron stores are obtained from maternal blood at 
the last weeks of the third trimester, the preterm neonates have lower iron stores. 
In consequence, these individuals are more prone to iron deficiency anemia in the 
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postnatal period, concomitantly to physiologic anemia. [37] Also, low birth-weight 
infants and those with perinatal blood loss are at risk of developing iron deficiency 
anemia. Other nutritional deficiencies that can imply the development of anemia in 
the newborn include folate, copper, vitamin B12, vitamin B6, vitamin A, vitamin C 
and vitamin E. [18, 38].
7.3 Congenital disorders of erythrocyte production
Diamond-Blackfan anemia (DFA) is a rare congenital syndrome that affects 
mostly the erythroid precursor in the bone marrow. DFA is characterized by severe 
anemia in infants, that is usually macrocytic or normocytic, with reticulocytopenia. 
Approximately 25% of patients are anemic at birth, and hydrops fetalis occurs 
rarely. Associated congenital abnormalities include triphalangeal or duplicated 
digits, abnormal facies, genitourinary, musculoskeletal, cardiac and ophthalmo-
logical abnormalities. Various mutations in genes encoding ribosomal proteins are 
responsible for the pathogenesis of DFA. [3, 39].
Fanconi’s anemia (FA) is a rare autosomal recessive disorder associated with 
bone marrow failure and increased susceptibility to leukemia and other types of 
cancer. Patients with FA usually present congenital malformations and have high 
sensitivity to alkylating agents and radiation. Various mutations are associated with 
FA, and all FA genes code for proteins that play roles in various cellular pathways, 
especially in DNA cross linking and repair. In the neonatal period, FA patients may 
present with cytopenias, congenital malformations, or both. [9, 40].
8. Diagnosis of anemia
The diagnosis of anemia in the newborn can be challenging, especially for those 
in intensive care. However, the accurate diagnosis and the determination of the 
underlining cause of the anemia is essential for adequate clinical management.
8.1 Clinical diagnosis
The diagnostic approach usually includes the patient history (familial, maternal, 
patient), physical examination and laboratory tests.
The patient history is based on familial and maternal medical history, preg-
nancy, delivery and postpartum period.
Familial history must be checked for the presence of any relatives with history 
of chronic anemia because genetic causes for neonatal anemia could be present such 
as Diamond-Blackfan and Fanconi anemia, enzymatic deficiencies and erythrocyte 
membrane defects.
Maternal medical history concerns the before pregnancy, pregnancy and 
postpartum. Bleeding disorders, history of chronic anemia, infections, medication 
use, trauma or vaginal bleeding, must be included on maternal medical history. 
Furthermore, maternal laboratory tests such as blood type, screening for antibodies 
and hemogram can provide useful information for the diagnostic approach of the 
anemia in the newborn.
As the twin-twin hemorrhage is a substantial cause of neonatal anemia due 
to blood loss, the type of pregnancy (multiple or singleton) is also relevant for 
diagnosis. [11].
The method of delivery and the presence of intrapartum intercurrences like 




The patient history contains information concerning age, gestational age at the 
delivery, sex, birthweight, history of infections, ventilatory support, medication 
and transfusions.
Physical examination of the anemic newborn must verify diminished activity, 
feeding difficulties and dyspnea at rest. Skin examination is necessary for check 
the presence of pallor, which is present generally in various types of anemia, and 
jaundice, which is associated with hemolytic anemias. Additionally, hepatospleno-
megaly presence is an important finding in physical examination, which is also an 
indicative of hemolytic anemia. [22].
9. Laboratory diagnosis
For the laboratory diagnosis of anemia, a stepwise diagnostic approach is 
recommended to avoid unnecessary tests. This approach is benefic for preventing 
iatrogenic blood loss of the newborn and other consequences of repeated blood 
withdrawals, and also reduces the costs for diagnosis. The laboratory tests for the 
diagnosis of neonatal anemia are presented in Figure 3.
The first step on the laboratory diagnosis is the establishment of the anemia, 
which concerns an adequate interpretation of a complete blood count consider-
ing proper reference values for the newborn infant age. Once there is a diagnosis 
of anemia, the second step is to determine the cause, which can be challenging, 
especially for preterm infants under intensive care. There are numerous laboratory 
tests that can be helpful to establish the cause of anemia. However, its choice will 
depend on the clinical examination, and also on the availability of tests where the 
NICU is located.
Reticulocyte count will provide useful information concerning the bone marrow 
capacity to produce new erythrocytes. Automated reticulocyte counts are more 
accurate than manual techniques because of the standardization of cell size and 
DNA content, which enables the identification of the number of reticulocytes per 
microliter of blood. [41].
Figure 3. 
Laboratory tests for diagnosis of neonatal anemia.
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During the first two weeks of life, the reticulocyte count decreases gradually. 
In infants with anemia, however, the bone marrow will attempt to compensate 
through increased erythropoietic activity, characterized by an elevated reticulo-
cyte count. If the erythropoiesis in the bone marrow production is impaired, the 
reticulocyte count will remain low. In the presence of anemia with low reticulocyte 
counts, a diagnosis of bone marrow suppression or dysfunction should be consid-
ered. The next steps may comprehend the nutritional deficiencies with a complete 
iron status and vitamin and other elements if necessary. [18].
Besides the reticulocyte count, the automated hematologic analyzers have useful 
parameters for the assessment of iron status, like the reticulocyte hemoglobin 
content (CHr) and immature reticulocyte fraction (IRF), which reflects the actual 
availability of iron for erythropoiesis. These parameters are helpful in the assess-
ment and early detection of anemia with no additional costs or need for more blood 
sampling. [42, 43].
To identify iron deficiency anemia, the hemoglobin concentration must be 
confirmed by other measurements of iron status. Iron status markers include: 
hemoglobin concentration, mean corpuscular hemoglobin concentration (MCHC), 
mean corpuscular volume (MCV), Chr, total iron-binding capacity, serum ferritin 
(SF) and transferrin saturation.
As SF is an acute-phase protein, its concentrations may be elevated in the pres-
ence of chronic inflammation, infection, malignancy, or liver disease. Because Chr 
is not affected by these factors or anemia of chronic disease, it is a preferable marker 
of iron status. It provides a measure of iron available to cells recently released from 
the bone marrow. [41, 44].
Serology for infectious congenital diseases associated with decreased erythro-
cyte production such as parvovirus B19, cytomegalovirus, syphilis and toxoplasmo-
sis should also be performed. Bone marrow aspirate/biopsy should be performed 
in the cases where de peripheral blood tests were not enough to establish a proper 
diagnosis of the cause of anemia. The congenital disorders of erythrocyte produc-
tion are also characterized by anemia with low reticulocyte counts. If there is a 
clinical suspicion of genetic disorders such Fanconi anemia and Diamond-Blackfan, 
specific molecular tests must be required. [39, 40].
In the anemic patient with a normal or elevated reticulocyte count, the next 
diagnostic steps should be focused on the hemolytic anemias.
Evaluation of the hemolytic anemia in newborn infants should include blood 
typing of the mother and the infant and direct antiglobulin testing (DAT), to detect 
immune-mediated hemolysis. [29].
Examination of the peripheral blood smear is also essential for a proper diag-
nosis of anemia. Neonatal erythrocytes show considerable heterogeneity, with 
a greater number of irregularly shaped RBCs, particularly in premature infants, 
which difficult the morphological analysis. Nucleated RBCs are present in the blood 
of healthy newborns on the first day of life. Finding 0 to 10 nucleated RBCs per 100 
WBCs is typical. In term infants, nucleated RBCs are rapidly cleared from the cir-
culation after birth. However, they persist in peripheral blood in small numbers for 
up to 1 week of life in preterm infants. [2] Increased counts are often the result of 
prematurity, anemia of different etiologies, increased erythropoiesis from chronic 
conditions, acute stress-mediated release from the marrow stores, and postnatal 
hypoxia. [45].
With significant hemolysis, fragmented red blood cells (schistocytes) are 
usually observed. Additionally, close attention should be paid to the presence of 
spherocytes or elliptocytes. Hereditary spherocytosis and elliptocytosis, the most 
commonly inherited membrane defects, can present as hemolytic anemia. [25–27] 




be paid to the mean corpuscular hemoglobin content (CHCM), which is usually 
increased (CHCM >36 g/dL). [28].
If there is clinical suspicion of an erythrocyte membrane defect, the osmotic 
fragility test will be helpful to confirm the diagnosis. Glycerol lysis and Pink tests 
are also used as first-line laboratory tests. Other more specialized tests for erythro-
cyte membrane defects include: flow cytometry, ektacytometry and SDS-PAGE of 
erythrocyte membrane proteins [28, 29, 46].
Observation of erythrocyte morphology can be useful in cases of erythrocyte 
enzymatic deficiencies. In the peripheral blood of individuals with G6PD defi-
ciency, bite cells and blister cells are usually seen, as a consequence of oxidative 
damage to the erythrocyte membrane. [30] The definitive diagnosis of G6PD 
deficiency will be determined with quantitative tests of enzyme activity. However, 
falsely negative tests in severe cases of enzymatic deficiency, where great amounts 
of erythrocytes are removed from the circulation by hemolysis. In those cases, if 
the clinical suspicion remains, the test for enzymatic activity must be repeated after 
3 months. [31].
As the hematologic features of pyruvate kinase deficiency are not different from 
other hemolytic anemias, the definitive diagnosis is obtained with direct quan-
titative tests for enzyme activity. If there is a clinical suspicion of an erythrocyte 
enzyme defect, both G6PD and PK tests should be performed. [31].
Other laboratory tests that are usually helpful for determining the presence 
of hemolytic anemia are: increased indirect bilirubinemia, increased LDH and 
decreased haptoglobin. [46].
Thalassemias are usually characterized by low mean corpuscular volume (MCV) 
and low mean corpuscular hemoglobin (MCH). It is also necessary to exclude iron 
deficiency anemia by performing a complete iron profile. Morphological features 
in the peripheral blood are usually helpful to sustain the suspect of thalassemia. 
Anisopoikilocytosis (variation in shape and size of the erythrocytes) with the pres-
ence of target cells are the most typical changes. Tear-drop cells and erythroblasts 
are usually seen in the most severe forms. Basophilic stippling and polychromasia 
are also frequent. For the investigation of thalassemia, hemoglobin electrophoresis 
and hemoglobin HPLC are used as the main screening tests. Confirmatory tests, if 
necessary, are made by DNA analysis for α and β-globin mutations. [47].
10. Issues related to preanalytical condition in laboratory diagnosis
The quality of laboratory test results is affected by preanalytical variables such 
as sample collection, specimen handling, sample size, and analytic interference. The 
most important precatalytic factors that influence the laboratory results of neonates 
and infants are the limited blood availability, the variation of results depending on 
blood sampling sites, and the effect of vigorous crying or exertion on hematologic 
test results. [2].
The total blood volume depends on the height and weight of the individual and, 
therefore, is markedly low in infants, especially in premature newborns. Repeatedly 
blood withdrawal is associated with iatrogenic anemia, thus, this practice must be 
avoided as much as possible. [16].
As the blood collection tubes contain a fixed amount of anticoagulant, collecting 
an amount of blood which is smaller than the recommended by the manufacturer 
may result in hemodilution or clotting and cause erroneous results. In order to 
avoid such problems, pediatric collection tubes for reduced volumes can be used. 
However, as most of pediatric tubes does not follow standard dimensions, its use 
brings challenges to clinical laboratories, including the need for manual handling, 
Neonatal Intensive Care Unit
12
Author details
Laura M. Dionisio1,2* and Thamires A. Dzirba1,2
1 State University of Ponta Grossa, Paraná, Brazil
2 Avenida General Carlos Cavalcanti, Uvaranas, Ponta Grossa, Brazil
*Address all correspondence to: mattana.laura@gmail.com; lmdionisio@uepg.br
because the hematology analyzers are not usually adapted to process those tubes 
automatically. In addition, blood clotting, hemolysis, and insufficient sample 
volume are common issues when dealing with neonatal specimens. [2, 48].
Hemolysis is the most frequent preanalytical issue, especially in neonatal 
patients. [49] The main cause of hemolysis in those patients is the site of collec-
tion, where de arterial catheter collections are associated with greater numbers of 
hemolyzed samples. [48].
The blood sampling site is also a relevant factor that influences the complete 
blood count results. Significant differences between capillary, venous and arterial 
sites have been reported. Thus, it is useful to concern the sample of collection for 
proper interpretation of the results. [50, 51].
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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